Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis
Open accessThe DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
CONTEXT: Concomitant obesity is common among patients with type 1 diabetes mellitus (T1DM), yet adjunctive therapy options are scarce. OBJECTIVE: We assess the efficacy and adverse outcomes of glucagon-like peptide 1 (GLP-1) analogues when used as adjunctive therapy for T1DM. METHOD: PubMed, EMBASE, Cochrane Central, and Scopus databases were searched for randomized controlled trials up to December 2022. Efficacy outcomes were A1c level, body weight, and total daily insulin (TDI) after ≥12 weeks of GLP-1 therapy. We also assessed 12 different adverse outcomes. Subgroup analysis was done for newly diagnosed or C-peptide positive (C-pos) patients. We report the certainty of evidence based on the GRADE assessment tool. RESULTS: A total of 24 studies using 4 different GLP-1 analogues with a total of 3377 patients were included. Liraglutide had the most substantial evidence with effect sizes on A1c (-0.09%/mg), weight (-2.2 kg/mg), and TDI (-4.32 IU/mg). Liraglutide dose was the greatest predictor of greater average weight loss and TDI decrease but was associated with higher odds of nausea (OR 6.5; 95% CI, 5.0-8.4) and ketosis (OR 1.8; 95% CI, 1.1-2.8). Odds of severe (OR 0.67; 95% CI, 0.43-1.04) or symptomatic hypoglycemia (OR 0.89; 95% CI, 0.53-1.51) were not significantly elevated. Among C-pos patients, greater A1c decrease (-0.51% vs -0.28%) but similar weight loss and TDI were seen. Effect sizes for exenatide were similar, but studies had higher risk of bias and safety data were sparse. CONCLUSION: Our meta-analysis supports therapeutic benefits of liraglutide for patients with T1DM mainly for weight loss and insulin dose reduction. Newly diagnosed or C-pos patients do not appear to experience greater weight loss benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“These findings are consistent with a 2023 meta-analysis showing that liraglutide was associated with a significantly increased odds of ketosis in patients with type 1 diabetes (OR 1.8; 95% CI, 1.1–2.8) [49].”
From Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes (2025) · cites this paper as [49]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings are consistent with a 2023 meta-analysis showing that liraglutide was associated with a significantly increased odds of ketosis in patients with type 1 diabetes (OR 1.8; 95% CI, 1.1–2.8) [49].”
From Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes (2025) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints
Harbord, R. M., Egger, M., & Sterne, J. A. C. (2006) · Statistics in Medicine · doi:10.1002/sim.2380 · Cited by 2,267
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Doing Meta-Analysis with R: A Hands-On Guide
Harrer, M., Cuijpers, P., Furukawa, T. A., & Ebert, D. D. (2021) · doi:10.1201/9781003107347 · Cited by 1,850
Quantifying publication bias in meta-analysis
Lin, L., & Chu, H. (2018) · Biometrics · doi:10.1111/biom.12817 · Cited by 1,674
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
Glycemic Control and Excess Mortality in Type 1 Diabetes
Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408214 · Cited by 964
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators (2016) · Diabetes Care · doi:10.2337/dc16-0691 · Cited by 347
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315
Ahrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0690 · Cited by 262
Effects of diet versus gastric bypass on metabolic function in diabetes
Yoshino, M., Kayser, B. D., Yoshino, J., Stein, R. I., Reeds, D., Eagon, J. C., Eckhouse, S. R., Watrous, J. D., Jain, M., Knight, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2003697 · Cited by 246
Hypoglycemia in Type 1 Diabetes Mellitus
Cryer, P. E. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.003 · Cited by 205
von Herrath, M., Bain, S. C., Bode, B., Clausen, J. O., Coppieters, K., Gaysina, L., Gumprecht, J., Hansen, T. K., Mathieu, C., Morales, C., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00019-x · Cited by 186
Obesity in people living with type 1 diabetes
Van der Schueren, B., Ellis, D., Faradji, R. N., Al-Ozairi, E., Rosen, J., & Mathieu, C. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00246-1 · Cited by 185
Dejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A. K., Holst, J. J., Tarnow, L., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00436-2 · Cited by 179
Kielgast, U., Krarup, T., Holst, J. J., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-0096 · Cited by 165
Type 1 diabetes mellitus: much progress, many opportunities
Powers, A. C. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142242 · Cited by 152
Rother, K. I., Spain, L. M., Wesley, R. A., Digon, B. J., Baron, A., Chen, K., Nelson, P., Dosch, H.-M., Palmer, J. P., Brooks-Worrell, B., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0773 · Cited by 133
Galipaud, M., Gillingham, M. A. F., & Dechaume‐Moncharmont, F. (2017) · Methods in Ecology and Evolution · doi:10.1111/2041-210x.12835 · Cited by 129
GLP-1 receptor agonist as a modulator of innate immunity
Chen, J., Mei, A., Wei, Y., Li, C., Qian, H., Min, X., Yang, H., Dong, L., Rao, X., & Zhong, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997578 · Cited by 120
Frandsen, C. S., Dejgaard, T. F., Holst, J. J., Andersen, H. U., Thorsteinsson, B., & Madsbad, S. (2015) · Diabetes Care · doi:10.2337/dc15-1037 · Cited by 103
Kumar, K. V. S. H., Shaikh, A., & Prusty, P. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.01.020 · Cited by 102
Kuhadiya, N. D., Dhindsa, S., Ghanim, H., Mehta, A., Makdissi, A., Batra, M., Sandhu, S., Hejna, J., Green, K., Bellini, N., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1136 · Cited by 101
Brock, C., Hansen, C. S., Karmisholt, J., Møller, H. J., Juhl, A., Farmer, A. D., Drewes, A. M., Riahi, S., Lervang, H. H., Jakobsen, P. E., et al. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14063 · Cited by 92
Ghanim, H., Batra, M., Green, K., Abuaysheh, S., Hejna, J., Makdissi, A., Borowski, R., Kuhadiya, N. D., Chaudhuri, A., & Dandona, P. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14090 · Cited by 86
Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes
Sarkar, G., Alattar, M., Brown, R. J., Quon, M. J., Harlan, D. M., & Rother, K. I. (2014) · Diabetes Care · doi:10.2337/dc13-1473 · Cited by 74
Dejgaard, T. F., Schmidt, S., Frandsen, C. S., Vistisen, D., Madsbad, S., Andersen, H. U., & Nørgaard, K. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13911 · Cited by 72
Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes
Kuhadiya, N. D., Ghanim, H., Mehta, A., Garg, M., Khan, S., Hejna, J., Torre, B., Makdissi, A., Chaudhuri, A., Batra, M., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1451 · Cited by 71
Wang, W., Liu, H., Xiao, S., Liu, S., Li, X., & Yu, P. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0282-3 · Cited by 70
Johansen, N. J., Dejgaard, T. F., Lund, A., Schlüntz, C., Frandsen, C. S., Forman, J. L., Wewer Albrechtsen, N. J., Holst, J. J., Pedersen-Bjergaard, U., Madsbad, S., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30030-9 · Cited by 70
Insulin's centenary: the birth of an idea
Hegele, R. A., & Maltman, G. M. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30337-5 · Cited by 64
Using information‐theoretic approaches for model selection in meta‐analysis
Cinar, O., Umbanhowar, J., Hoeksema, J. D., & Viechtbauer, W. (2021) · Research Synthesis Methods · doi:10.1002/jrsm.1489 · Cited by 61
GLP-1 Agonists in Type 1 Diabetes Mellitus
Janzen, K. M., Steuber, T. D., & Nisly, S. A. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016651279 · Cited by 53
Patoulias, D., Doumas, M. N., Kotsis, V., Stavropoulos, K., Imprialos, K. P., Zografou, I., Petidis, K., Bakatselos, S., & Karagiannis, A. I. (2020) · Current Diabetes Reviews · doi:10.2174/1573399815666190614141918 · Cited by 53
Dejgaard, T. F., von Scholten, B. J., Christiansen, E., Kreiner, F. F., Bardtrum, L., von Herrath, M., Mathieu, C., Madsbad, S., & ADJUNCT ONE and ADJUNCT TWO Investigators (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14532 · Cited by 48
Pozzilli, P., Bosi, E., Cirkel, D., Harris, J., Leech, N., Tinahones, F. J., Vantyghem, M.-C., Vlasakakis, G., Ziegler, A.-G., & Janmohamed, S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa149 · Cited by 45
Avgerinos, I., Manolopoulos, A., Michailidis, T., Kitsios, K., Liakos, A., Karagiannis, T., Dimitrakopoulos, K., Matthews, D. R., Tsapas, A., & Bekiari, E. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14291 · Cited by 44
Pieber, T. R., Deller, S., Korsatko, S., Jensen, L., Christiansen, E., Madsen, J., & Heller, S. R. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12473 · Cited by 43
Herold, K. C., Reynolds, J., Dziura, J., Baidal, D., Gaglia, J., Gitelman, S. E., Gottlieb, P. A., Marks, J., Philipson, L. H., Pop‐Busui, R., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14121 · Cited by 41
Yang, Z., Yu, M., Mei, M., Chen, C., Lv, Y., Xiang, L., & Li, R. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.10.003 · Cited by 37
Tandon, S., Ayis, S. A., Hopkins, D. L., Harding, S., & Stadler, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14221 · Cited by 32
Jiang, L., Wang, S.-Q., Ding, B., Zhu, J., Jing, T., Ye, L., Lee, K., Wu, J., & Ma, J. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0765-0 · Cited by 29
Dubé, M., D'Amours, M., & Weisnagel, S. J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14050 · Cited by 25
Kim, Y. J., Hwang, S. D., & Lim, S. K. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00553 · Cited by 24
Liraglutide for treating type 1 diabetes
Dejgaard, T. F., Frandsen, C. S., Holst, J. J., & Madsbad, S. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1160050 · Cited by 22
Targeting the Pancreatic α-Cell to Prevent Hypoglycemia in Type 1 Diabetes
Panzer, J. K., & Caicedo, A. (2021) · Diabetes · doi:10.2337/dbi20-0048 · Cited by 21
van Meijel, L. A., Rooijackers, H. M. M., Tack, C. J., & de Galan, B. E. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00087 · Cited by 17
Doggrell, S. A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1519547 · Cited by 16
Type 1 diabetes drug was withdrawn because of a “commercial conflict of interest,” charity argues
Mahase, E. (2022) · BMJ · doi:10.1136/bmj.o373 · Cited by 12
Zenz, S., Regittnig, W., Boulgaropoulos, B., Augustin, T., Brunner, M., Korsatko, S., Münzker, J., Narath, S. H., Raml, R., Magnes, C., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac369 · Cited by 11
Ballav, C., Dhere, A., Kennedy, I., Agbaje, O. F., White, S. J., Franklin, R. H., Hartmann, B., Holst, J. J., Holman, R. R., & Owen, K. R. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.130 · Cited by 10
Dandona, P., Ghanim, H., Kuhadiya, N. D., Shah, T. J., HEJNA, J. M., Makdissi, A., Batra, M., & Chaudhuri, A. (2018) · Diabetes · doi:10.2337/db18-3-lb · Cited by 9
Dejgaard, T. F., Frandsen, C. S., Kielgast, U. L., Andersen, H. U., Thorsteinsson, B., Krarup, T., Holst, J. J., & Madsbad, S. (2019) · Diabetes · doi:10.2337/db19-59-or · Cited by 5
Use of Pramlintide: The Patient's Perspective
Want, L. L. (2006) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721706288249 · Cited by 4
Yamada, T., Mori, R., Hosoe, J., Shojima, N., Kamata, R., Ishinohachi, K., Yamauchi, T., Tanikawa, Y., & Kadowaki, T. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013164 · Cited by 2
Replication Data for: Use of GLP-1 agonists in T1DM: Meta-analysis
Park, J. (2023) · Harvard Dataverse · doi:10.7910/dvn/yyejqa · Cited by 1
Self-citationExplaining heterogeneity in meta-analysis: a comparison of methods
Thompson, S. G., & Sharp, S. J. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19991030)18:20
Research works printed but not linked: 3
- Abstracts of the 48th EASD (European Association for the Study of Diabetes) annual meeting of the European Association for the Study of Diabetes. October 1-5, 2012. Berlin, Germany. Diabetologia. 2012;55(Suppl 1):S7-S537.
- Schünemann H, Brożek J, Guyatt G, Oxman A, eds. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Updated October 2013. Updated October 2013. The GRADE Working Group; 2013. Available from guidelinedevelopment.org/handbook.
- Heller SR, Korsatko S, Gurban J, et al. Liraglutide as adjunct to in- sulin in type 1 diabetes: effects on glycemic control and safety in a randomized, double-blind, crossover trial. Diabetes. 2013; 62(Suppl 1):A258-A259.
Cited by
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Eichorst, B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s005 · Cited by 305
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s005 · Cited by 277
New advances in type 1 diabetes
Subramanian, S., Khan, F., & Hirsch, I. B. (2024) · BMJ · doi:10.1136/bmj-2023-075681 · Cited by 88
Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events
He, L., Li, Q., Yang, Y., Li, J., Luo, W., Huang, Y., & Zhong, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1416985 · Cited by 40
Shah, V. N., Peters, A. L., Umpierrez, G. E., Sherr, J. L., Akturk, H. K., Aleppo, G., Bally, L., Cengiz, E., Cinar, A., Dungan, K., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241291512 · Cited by 36
“55 Symptomatic, but not severe, hypoglycemic episodes were more frequent with liraglutide therapy.”
Metadata
- Authors
- Park, J., Ntelis, S., Yunasan, E., Downton, K. D., Yip, T. C.-F., Munir, K. M., & Haq, N.
- Affiliations
- University of Maryland, Baltimore (US)
- Chinese University of Hong Kong (HK)
- Chase Brexton Health Care (US)
- Corresponding author
- Park, Jeayoung
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2023-08-10
- Volume
- 109
- Issue
- 1
- Pages
- 279-292
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W4385716144
- Cited by
- 69
- References
- 64
- Citations by year
- 2026: 17 · 2025: 26 · 2024: 25 · 2023: 1
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- glucagon-like peptide-1 analogues, type 1 diabetes, adjunctive therapy, liraglutide, exenatide, obesity, weight loss, insulin dose reduction, glycemic control, hypoglycemia, nausea, ketosis, newly diagnosed type 1 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Venoms, Weight Loss, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.